Susan Dent
About
Susan Dent is a scholar working on Oncology, Cardiology and Cardiovascular Medicine and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Susan Dent has authored 138 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 78 papers in Oncology, 60 papers in Cardiology and Cardiovascular Medicine and 43 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Susan Dent's work include Chemotherapy-induced cardiotoxicity and mitigation (55 papers), Cancer Treatment and Pharmacology (36 papers) and HER2/EGFR in Cancer Research (29 papers). Susan Dent is often cited by papers focused on Chemotherapy-induced cardiotoxicity and mitigation (55 papers), Cancer Treatment and Pharmacology (36 papers) and HER2/EGFR in Cancer Research (29 papers). Susan Dent collaborates with scholars based in United States, Canada and United Kingdom. Susan Dent's co-authors include Daniel J. Lenihan, Daniela Cardinale, Carlo M. Cipolla, Olexiy Aseyev, Giuseppe Curigliano, Carmen Criscitiello, Ana Barac, Kathleen I. Pritchard, Bonnie Ky and Theresa M. Beckie and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and Journal of the American College of Cardiology.
In The Last Decade
Susan Dent
126 papers receiving 4.2k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Susan Dent United States | 34 | 2.1k | 1.9k | 945 | 698 | 658 | 138 | 4.3k | ||
| Ana Barac United States | 38 | 1.6k 0.8× | 2.9k 1.5× | 658 0.7× | 856 1.2× | 850 1.3× | 157 | 4.8k | ||
| Joseph R. Carver United States | 29 | 1.8k 0.9× | 4.5k 2.4× | 846 0.9× | 1.3k 1.9× | 737 1.1× | 81 | 6.0k | ||
| Saverio Cinieri Italy | 32 | 2.5k 1.2× | 692 0.4× | 930 1.0× | 322 0.5× | 1.0k 1.5× | 206 | 4.3k | ||
| Adedayo A. Onitilo United States | 28 | 1.7k 0.8× | 551 0.3× | 619 0.7× | 360 0.5× | 775 1.2× | 167 | 3.7k | ||
| Michael S. Ewer United States | 35 | 3.8k 1.8× | 5.5k 2.9× | 1.5k 1.6× | 1.2k 1.7× | 1.1k 1.6× | 78 | 7.6k | ||
| Erica L. Mayer United States | 31 | 2.6k 1.3× | 397 0.2× | 997 1.1× | 297 0.4× | 1.4k 2.1× | 144 | 4.7k | ||
| Tommy� Fornander Sweden | 45 | 2.9k 1.4× | 654 0.4× | 1.2k 1.3× | 767 1.1× | 1.2k 1.8× | 133 | 6.5k | ||
| Daniel J. Lenihan United States | 45 | 3.9k 1.9× | 6.8k 3.7× | 1.6k 1.7× | 1.8k 2.6× | 1.6k 2.4× | 232 | 9.7k | ||
| Franco Nolè Italy | 37 | 3.3k 1.6× | 469 0.3× | 1.5k 1.6× | 595 0.9× | 693 1.1× | 176 | 5.1k | ||
| Peter Barrett‐Lee United Kingdom | 35 | 2.6k 1.2× | 270 0.1× | 671 0.7× | 828 1.2× | 885 1.3× | 121 | 5.0k |
Countries citing papers authored by Susan Dent
Since
Specialization
Citations
This map shows the geographic impact of Susan Dent's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susan Dent with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susan Dent more than expected).
Fields of papers citing papers by Susan Dent
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Susan Dent. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susan Dent. The network helps show where Susan Dent may publish in the future.
Co-authorship network of co-authors of Susan Dent
This figure shows the co-authorship network connecting the top 25 collaborators of Susan Dent. A scholar is included among the top collaborators of Susan Dent based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susan Dent. Susan Dent is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Blaes, Anne, et al.. (2025). Cardiotoxic Effects of Antibody Drug Conjugates vs Standard Chemotherapy in ERBB2 -Positive Advanced Breast Cancer. JAMA Network Open. 8(11). e2540336–e2540336.
2.
Ganatra, Sarju, Ana Barac, Saro H. Armenian, et al.. (2025). Diagnosis and Management of Cardiovascular Adverse Effects of Targeted Oncology Therapies: Bruton’s Tyrosine Kinase, Immune Checkpoint, and Vascular Endothelial Growth Factor Inhibitors: 2025 ACC Concise Clinical Guidance. Journal of the American College of Cardiology. 87(5). 654–682.
3.
Adams, Scott C., Jessica M. Scott, Michelle B. Nadler, et al.. (2025). Cardio-oncology rehabilitation and exercise: evidence, priorities, and research standards from the ICOS-CORE working group. European Heart Journal. 46(29). 2847–2865.
4.
Bloom, Michelle, Jose Alvarez‐Cardona, Sarju Ganatra, et al.. (2024). How to utilize current guidelines to manage patients with cancer at high risk for heart failure. Cardio-Oncology. 10(1). 63–63.
5.
Dent, Susan, Avirup Guha, Stella Stergiopoulos, et al.. (2024). Abstract PO1-04-13: CARDIAC-STAR: Prevalence of Cardiovascular Comorbidities in Hormone Receptor Positive Human Epidermal Growth Factor Negative metaStatic breasT cAnceR. Cancer Research. 84(9_Supplement). PO1–4.
6.
Stabellini, Nickolas, Jennifer Cullen, Márcio Sommer Bittencourt, et al.. (2024). Allostatic Load/Chronic Stress and Cardiovascular Outcomes in Patients Diagnosed With Breast, Lung, or Colorectal Cancer. Journal of the American Heart Association. 13(14). e033295–e033295.
7.
Dent, Susan, et al.. (2024). Assessment of efficacy and safety of dose-dense doxorubicin and cyclophosphamide (ddAC) in combination with immunotherapy in early-stage triple-negative breast cancer. Breast Cancer Research and Treatment. 207(1). 179–185.
8.
Thomas, Alexandra, Nathaniel S. O’Connell, Carolyn J. Park, et al.. (2023). Cardiovascular impact of near complete estrogen deprivation in premenopausal women with breast cancer: The CROWN study. American Heart Journal. 267. 33–43.
9.
Chen, Jessica W., William Jacot, Javier Cortés, et al.. (2023). ER +, HER2 − advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes. Molecular Oncology. 17(10). 2000–2016.
10.
Stabellini, Nickolas, Jennifer Cullen, Justin X. Moore, et al.. (2023). Social Determinants of Health Data Improve the Prediction of Cardiac Outcomes in Females with Breast Cancer. Cancers. 15(18). 4630–4630.
11.
Leong, Darryl P., Nazanin Aghel, Peter Ellis, et al.. (2023). Cardiac Interventions in Patients With Active, Advanced Solid and Hematologic Malignancies. JACC CardioOncology. 5(4). 415–430.
12.
Avula, Vennela, Garima Sharma, Mikhail Kosiborod, et al.. (2023). SGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Cancer Therapy–Related Cardiac Dysfunction. JACC Heart Failure. 12(1). 67–78.
13.
Zullig, Leah L., Benjamin Neely, Terry Hyslop, et al.. (2021). Low-touch, team-based care for co-morbidity management in cancer patients: the ONE TEAM randomized controlled trial. BMC Family Practice. 22(1). 234–234.
14.
Dent, Susan, et al.. (2021). Cardiovascular Toxicity of Novel HER2-Targeted Therapies in the Treatment of Breast Cancer. Current Oncology Reports. 23(11). 128–128.
15.
Rao, Vijay U., David J. Reeves, Atul Chugh, et al.. (2021). Clinical Approach to Cardiovascular Toxicity of Oral Antineoplastic Agents. Journal of the American College of Cardiology. 77(21). 2693–2716.
16.
Addison, Daniel, Courtney Campbell, Avirup Guha, et al.. (2020). Cardio‐Oncology in the Era of the COVID‐19 Pandemic and Beyond. Journal of the American Heart Association. 9(19). e017787–e017787.
17.
Melloni, Chiara, Gretchen Kimmick, Taofik Oyekunle, et al.. (2019). Abstract 15660: Statin Use is Associated With Increased Overall Survival in Patients With Colorectal Cancer: Findings From a Cohort of 29,498 United States Veterans. Circulation.
18.
Baselga, José, Susan Dent, Javier Cortés, et al.. (2018). Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA -mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER.. Journal of Clinical Oncology. 36(18_suppl). LBA1006–LBA1006.
19.
Sulpher, Jeffrey, Rebecca Dent, & Susan Dent. (2014). Neoadjuvant chemotherapy in breast cancer. Current Opinion in Supportive and Palliative Care. 8(1). 59–63.
20.
Lavasani, Sayeh, John R. Mackey, Kathleen I. Pritchard, et al.. (2010). Optimizing the Management of her2-Positive Early Breast Cancer: The Clinical Reality. Current Oncology. 17(4). 20–33.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Ana Barac Breakdown of academic impact, for papers by Joseph R. Carver Breakdown of academic impact, for papers by Saverio Cinieri Breakdown of academic impact, for papers by Adedayo A. Onitilo Breakdown of academic impact, for papers by Michael S. Ewer Breakdown of academic impact, for papers by Erica L. Mayer Breakdown of academic impact, for papers by Tommy� Fornander Breakdown of academic impact, for papers by Daniel J. Lenihan Breakdown of academic impact, for papers by Franco Nolè Breakdown of academic impact, for papers by Peter Barrett‐Lee